Home Newsletter Honored Guests Blog About Us Work With Us Sponsor & Advertise Be a Guest The Production Suite Get the Briefing
Skip to main content

Open Door Salon

Q2 2026 Edition

Be a thought leader · Get your FREE quarterly briefing. No strings. Ever.

What thought leaders in life-sciences are actually saying. In four pages.

The Biosecure Act’s real timeline, the line between real AI in drug discovery and marketing language, and why a cell therapy costs $50,000 in India and seven figures in the US. Ten minutes, in your inbox. Free.



No spam. Just the weekly Open Door Salon newsletter on Substack. Unsubscribe anytime.

Inside this edition

  • The Biosecure Act’s real timeline: Colin Zick (Foley Hoag) & Anne Herold Li (Brownstein Hyatt Farber Schreck)
  • AI in drug discovery, substance vs window dressing: Mike Goguen (Two Bear Capital, ex-Sequoia) & Rob Williamson (Traverse Therapeutics)
  • Why manufacturing cost stopped being the real barrier: Andy Holt (Viralgen) & Phil Vanek (ISCT)

Six life-sciences operators, on the record, distilled by Lori Ellis, host of Open Door Salon.

The Briefing

Need the life-sciences signal but short on time?

Get a free quarterly briefing: four pages on what life-sciences operators are actually saying about Biosecure, AI hype vs. substance, and the $50,000 cell-therapy question. Ten minutes, in your inbox.